Overactive bladder
Conditions
Interventions
None listed
Sponsors
FUN(Fukuoka Urology Network)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Benign prostatic hyperplasia 2) Patients who have overactive bladder even after administering alfa1-blocker (Silodosin or Naftopidil) for more than 4 weeks 3) Age more than 50 years 4) Prostate volume is more than 20mL or less than 50ml 5) Patients from whom we have received consent
Exclusion criteria
Exclusion criteria: 1) Patients who have administered prohibited substances or done prohibited therapy within the 4 weeks before enrollment. (Sex hormone drug and 5-alpha reductase inhibitor within the 52 weeks before enrollment.) 2) Patients who changed the dosage or usage of a restricted medicine within the 4 weeks before enrollment 3) Patients with prostate cancer, neurogenic bladder, urethra stricture, chronic prostatitis, symptomatic urinary tract infection, urinary tract stones and interstitial cystitis 4) Patients with anuresis 5) Patients with pyloristenosis, constriction of dodecadactylon, construction of enteron and adynamic ileus 6) Patients with deterioration of enterokinesis 7) Patients with angle-closure glaucoma 8) Patients with myasthenia gravis 9) Patients with serious cardiac disorder, serious liver dysfunction and serious kidney dysfunction 10) Patients with history of hypersensitive reaction to anticholinergic agents 11) Residual urine volume is more than 50mL 12) Patients in which it has been confirmed that Qmax is less than 5mL/s 13) Patients with Polyuria 14) Any other patients who are regarded as unsuitable for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of total OABSS score | — |
Countries
Japan
Contacts
Public ContactNarihito Seki
Kyushu Central Hospital Urology
Outcome results
None listed